Skip to main content

Table 4 Combination of two targeted drug Trials

From: The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of

NCT No. Drug1 Drug2 Targets Year Phase Region Results
NCT03114527 Ribociclib Everolimus CDK, mTOR 2017 Phase II US No
NCT02343172 HDM201 LEE011 MDM2, CDK 2015 Phase I| Phase II US No
NCT02008877 ganetespib Sirolimus HSP90, CD105 2013 Phase I|Phase II US No
NCT01804374 Sorafenib Everolimus Multi-RTK, mTOR 2011 Phase II Europe No
NCT01281865 everolimus imatinib Multi-RTK, mTOR 2011 Phase I|Phase II US Yes
NCT01206140 Selumetinib Temsirolimus MEK, mTOR 2010 Phase II US Yes
NCT01016015 Cixutumumab Temsirolimus mTOR, IGF-1R 2009 Phase II US Yes
NCT00937495 vorinostat bortezomib HDAC,26S proteasome 2009 Phase II US Yes
  1. Abbreviations: CDK cyclin-dependent kinase, mTOR mammalian target of rapamycin, MDM2 Mouse double minute 2 homolog, HSP90 heat shock protein 90, RTK receptor tyrosine kinase, MEK Mitogen-activated protein kinase kinase, IGF-1R Insulin-like growth factor 1 receptor, HDAC Histone deacetylase